Landos' IBD drug well-tolerated — 6 study insights

Landos Biopharma reported results from its phase 1 trial of BT-11, an ulcerative colitis and Crohn's disease treatment.

Here's what you should know:

1. BT-11 is an orally-active, gut-restricted therapeutic. Researchers conducted a randomized, double-blind trial of 70 patients to assess the drug's safety.

2. The drug was well-tolerated in all 70 patients, with no dose-limiting toxicities.

3. Adverse events in the BT group were like that of the placebo group.

4. Researchers tested BT-11 doses between 7 mg/kg and 100 mg/kg. They did not reach a maximum tolerated dose.

5. Landos Chairman and CEO Josep Bassaganya-Riera, PhD, said, "The results of our Phase 1 study provide the first-in-human clinical data in support of BT-11 as a novel oral treatment for IBD. We are pleased to see that BT-11 was well-tolerated and safe in healthy volunteers."

6. Landos will begin a phase 2 study in 2019.

More articles on gastroenterology:
The PE arms race — From the deal heard round the world to what's next in GI
The strategy behind Pardee UNC's $16M ASC
ASC supply chain tip of the day: Find an accountability structure

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months